Global Endoscope + Radiofrequency Ablation (RFA) Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Endoscope + Radiofrequency Ablation (RFA) Market Research Report 2024
Radiofrequency ablation (RFA) is one of the most promising ablative techniques for BE. The technique uses a bipolar electrode that is available as a balloon-based device for primary circumferential ablation or as a cap-based device that can be mounted on the tip of the endoscope for focal ablation.
According to MRAResearch’s new survey, global Endoscope + Radiofrequency Ablation (RFA) market is projected to reach US$ 5339.2 million in 2033, increasing from US$ 3575.2 million in 2022, with the CAGR of 5.4% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Endoscope + Radiofrequency Ablation (RFA) market research.
The key factors that boost the growth of the global endoscope + radiofrequency ablation (RFA) market include upsurge in demand for novel treatment methods for patients suffering from cancer, cardiovascular diseases, and disorders associated with chronic pain along with the benefits offered by this advanced treatment modality. Several research studies have concluded that radiofrequency ablation (RFA) treatment efficiently creates lesion in the targeted body parts while maintaining short procedure durations.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Endoscope + Radiofrequency Ablation (RFA) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Boston Scientific Corporation Conmed Corporation
Medtronic Plc (Covidien Plc)
Smith and Nephew Plc
Stryker Corporation
Halyard Health
Abbott Laboratories (St. Jude Medical, Inc.)
AngioDynamics
Hologic
AtriCure
Segment by Type
Focal Ablation
Others
Cardiology Application
Pain Management
Oncology Application
Other Application
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Endoscope + Radiofrequency Ablation (RFA) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global Endoscope + Radiofrequency Ablation (RFA) market is projected to reach US$ 5339.2 million in 2033, increasing from US$ 3575.2 million in 2022, with the CAGR of 5.4% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Endoscope + Radiofrequency Ablation (RFA) market research.
The key factors that boost the growth of the global endoscope + radiofrequency ablation (RFA) market include upsurge in demand for novel treatment methods for patients suffering from cancer, cardiovascular diseases, and disorders associated with chronic pain along with the benefits offered by this advanced treatment modality. Several research studies have concluded that radiofrequency ablation (RFA) treatment efficiently creates lesion in the targeted body parts while maintaining short procedure durations.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Endoscope + Radiofrequency Ablation (RFA) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Boston Scientific Corporation Conmed Corporation
Medtronic Plc (Covidien Plc)
Smith and Nephew Plc
Stryker Corporation
Halyard Health
Abbott Laboratories (St. Jude Medical, Inc.)
AngioDynamics
Hologic
AtriCure
Segment by Type
Focal Ablation
Others
Segment by Application
Cardiology Application
Pain Management
Oncology Application
Other Application
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Endoscope + Radiofrequency Ablation (RFA) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source